Note 9 – Related Party Transactions

In addition to the transactions discussed in Notes 7, 8 and 15, the Company had related party transactions during the years ended December 31, 2017 and 2016 as follows:

The Company has a consulting agreement with Alcimede pursuant to which Mr. Lagan provides services as the Company’s Chief Executive Officer. Alcimede was paid $0.4 million and $0.6 million in consulting fees for the years ended December 31, 2017 and 2016, respectively.

During the second quarter of 2016, the Company received a short-term advance from Jason Adams, the Company’s then Chief Financial Officer, in the amount of $50,000, all of which was repaid during the second quarter.

On August 1, 2015, Medytox entered into a non-exclusive consulting agreement with Monarch Capital, LLC (“Monarch”). Michael Goldberg, at the time a director of Medytox and a director of the Company until his resignation on April 24, 2017, is the Managing Director of Monarch. Under this agreement, Monarch provided business and financial advice. The agreement expired on August 31, 2017. Monarch was paid approximately $139,000 and $150,000 for consulting fees pursuant to this agreement for the years ended December 31, 2017 and 2016, respectively.

Dr. Thomas Mendolia, the former Chief Executive Officer of the Company’s laboratories and at the time a principal stockholder, was reimbursed $26,765 for certain operating expenses and asset purchases paid by Dr. Mendolia on the Company’s behalf in the year ended December 31, 2016.

The terms of the foregoing transactions, including those discussed in Notes 7, 8, 12 and 14, are not necessarily indicative of those that would have been agreed to with unrelated parties for similar transactions.